Bristol Myers Squibb’s Celgene subsidiary has removed purchasing limits due to demand-related supply constraints on its injectable acute myeloid leukemia (AML) drug Vidaza that have been in place since May 2020.
BMS announced the switch back to normal sales in a notice to 340B covered entities dated Oct. 1 on the U.S. Health Resources and Services Administration (HRSA) website. “At current time all limitations on purchasing of Vizada in the United States have been removed for 340B and non-340B entities,” the notice says. For roughly a year and a half, reduced sales to 340B covered entities and non-340B buyers have been based on customers’ historical purchasing patterns.
There are roughly 10 generic versions for the injectable form of Vidaza, most of them currently in short supply, according to the American Society of Health-System Pharmacists.
There is an oral version of Vidaza called Onureg, but it is only for adults who are in first complete remission. The two are not interchangeable.
